Background--Atherosclerotic cardiovascular disease (ASCVD) and cancer are among the leading causes of economic burden, morbidity, and mortality in the United States. We aimed to quantify the overall impact of cardiovascular modifiable risk factor (CRF) profile on healthcare expenditures among those with and without ASCVD and/or cancer.
A therosclerotic cardiovascular disease (ASCVD) and cancer are among the leading causes of economic burden, morbidity, and mortality in the United States. 1 Nearly half of all deaths in the United States can be attributed to either cancer or ASCVD. The annual direct and indirect cost of ASCVD and cancer in the United States is an estimated $844.4 billion dollars, which is projected to double by 2030. [2] [3] [4] In addition to an aging population, a growing number of cancer survivors are expected to increase from 15.5 to 20 million over the next decade, and in whom ASCVD is one of the most common causes of non-cancer-related deaths. 5, 6 An emerging paradigm, which continues to evolve, is the inextricable link between ASCVD and cancer through common modifiable risk factors such as tobacco use, obesity, diabetes mellitus, diet quality, and physical activity. A scientific statement from 2004 endorsed by the American Heart Association, American Cancer Society, and American Diabetes Association called for more collaborative and effective preventive healthcare strategies by targeting these shared risk factors. 7 Cancer survivorship begins at the time of diagnosis, and many face increased healthcare expenditures compared with individuals without a history of cancer, which can lead to a reduced use of preventive services and preventive medications. [8] [9] [10] Although there are some reports highlighting optimal cardiovascular risk factor (CRF) profile in middle age being associated with reduced cardiovascular costs later in life, the impact of ASCVD and global CRF on healthcare costs and resource utilization among cancer survivors is not well described. 11, 12 The goal of this study was to detail the healthcare costs for cancer patients across the spectrum of ASCVD status and varying modifiable CRF profiles in a nationally representative population. We hypothesized that a favorable CRF profile will be associated with significantly lower direct healthcare expenditure and resource utilization in cancer survivors.
Methods Design
The Medical Expenditure Panel Survey (MEPS) data sets and codebooks used for this study are available to the public, and can be accessed on the Agency for Healthcare Research and Quality website at: https://meps.ahrq.gov/me psweb/. 13 We conducted a retrospective study that utilized data from the MEPS, 2012 and 2013. The MEPS, led by the Agency for Healthcare Research and Quality, is a set of largescale, national survey about individuals and families, their medical providers, and their employers. The Household Component of the MEPS collects data about health services used, their frequency and cost, charges, source of payment, income, employment, as well as ample data on insurance used by and available to US workers. 13 The MEPS respondents are enrolled for 2 years of data collection, with a new panel beginning each year. The sampling frame for the MEPSHousehold Component is drawn from respondents to the National Health Interview Survey and the design of the MEPSHousehold Component survey includes sampling weights, stratification, and clustering. The MEPS sampling weights incorporate adjustment for the complex sample design and reflect survey nonresponse and population totals from the Current Population Survey. 13 In order to increase the study's population, we merged 2012 and 2013 data, and used (from the MEPS Household Component) the full-year consolidated data files and medical conditions files. The full-year consolidated data files include most demographics on a person-level, while the medical conditions files include each diagnosis a person has, which after being transcribed verbatim at each survey, are translated into International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) by professional coders. MEPS also allows categorization by Clinical Classification Software, a tool from Healthcare Cost and Utilization Project that groups ICD-9-CM codes into meaningful clinical categories. 14 All files were linked together in order to determine accurate results for each individual. Since MEPS information is publically available, de-identified data-files, it was exempt from institutional review board review. 15 
Participants
Initially, 75 402 individuals were surveyed between 2012 and 2013. We limited our study population to US adults ≥40 years of age (because of the low prevalence of established ASCVD among adults aged 18-39 years), who had a positive sampling weight (to best estimate nationally representative results), and a body mass index≥18.5 kg/m 2 (given that they often represent a sicker patient population), reaching a study population of 25 275 noninstitutionalized individuals.
Clinical Perspective
What Is New?
• In this study, we noted a higher prevalence of atherosclerotic cardiovascular disease as well as poor cardiovascular disease risk profile among cancer survivors.
• Absence of atherosclerotic cardiovascular disease and presence of optimal cardiovascular risk profile among cancer survivors was associated with a significantly lower overall medical expenditure and resource utilization, including prescription medications, hospitalizations, emergency department, and outpatient visits.
What Are the Clinical Implications?
• These results support population healthcare models emphasizing prevention of atherosclerotic cardiovascular disease and improvement of cardiovascular risk factor profiles to favorably impact the rising burden of healthcare expenditures among cancer survivors.
Study Variables
Individuals in the study population were classified into our outcome variables based on presence of either a prior diagnosis (ascertained by ICD-9-CM or Clinical Classification Software codes, 
Statistical Analysis
For comparison of demographic characteristics in our sample, v 2 tests were performed. 17 Because of the right-skewedness of expenditures data (i.e. most expenditures are seen in only a small proportion of the population), 2-part models were utilized to study expenditures. 18 Two-part models are often used to model healthcare expenditures, and are the product of (1) the probability that any given individual had any expenditures; and (2) their mean expenditures. 19 The first part of the model consists of a probabilistic regression model (probit), which estimates the probability of zero versus positive expenditures. Contingent upon having a positive annual healthcare expenditure, a generalized linear model (glm) with gamma distribution and a logarithmic-link function estimates the average expenditure per capita 19, 20 ; we determined the distribution of the glm using the modified Park Test. 21 For resource utilization, unadjusted and adjusted logistic regression models were utilized. Unadjusted means and proportions were calculated, adjusting for the survey design and sampling weight. For all statistical analyses, P<0.05 was considered statistically significant. All analyses were carried out using Stata â , version 13.1 (StataCorp, LP, College Station, TX). Total and Marginal expenditures were estimated using the "margins" command after the 2-part models. 19 All analyses took into consideration the MEPS complex survey design.
Results

Population Characteristics
The final study population consisted of 27 275 participants ≥40 years of age (59AE9 years, 52% female), which translates to %141.6 million US adults; demographic information is presented in Table 1 . Overall, 14% had cancer, translating to 25.6 million of the noninstitutionalized adult population in the United States. Those with cancer were more likely to be older, female, have ASCVD, have poor CRF profile, and a higher burden of comorbid conditions. In the total study population with cancer, 1434 (26.7%) had optimal, 2361 (50.6%) had average, and 1126 (22.7%) had poor CRF profile, translating to 6.8, 12.9, and 5.8 million individuals in the United States, respectively.
Healthcare Expenditures
Average per-capita healthcare expenditures estimated using univariate and multivariate models by CRF profile, cancer, and ASCVD status are shown in Table 2 . Presence of cancer was associated with increased overall healthcare expenditures compared with those without cancer across the spectrum of ASCVD status and CRF profile. Cancer participants without ASCVD and a poor CRF profile had a mean annual expenditure of $11 191 compared with $8116 among those with an optimal CRF profile ( 
Healthcare Resource Utilization
Discussion
Previous studies have evaluated the financial burden associated with cancer survivorship 4, 8, 10, 22, 23 ; however, to the authors' knowledge, this is the first attempt to contextualize the economic impact of ASCVD and CRF profiles on cancer survivors in a contemporary national representative sample of the US population. We found a higher prevalence of ASCVD (25% versus 14%) and lower likelihood of an optimal CRF profile (27% versus 38%) among cancer survivors compared with those without cancer. Additionally, we found significantly reduced healthcare utilization and expenditures among cancer survivors without ASCVD, and especially among those with optimal CRF profile.
Our results are consistent with prior reports highlighting the increased burden of ASCVD and CRF in cancer survivors. 5, [24] [25] [26] Several contributing factors to this observation include common risk factors, rapidly growing survivorship population with the majority over the age of 65, and potentially cardiotoxic effects from cancer therapies themselves. 6, 24, 27 Many of the major shared risk factors between cancer and ASCVD are incorporated into the American Heart Association's "Strategic Impact Goals for 2020," which introduced the Life's Simple 7 (smoking status, physical activity, eating pattern, body weight, blood cholesterol, blood glucose, and blood pressure) as a population-level health-promotion strategy that has been shown to improve overall cardiovascular outcomes. 28, 29 Additionally, adherence to more components in American Heart Association's Life's Simple 7 appears to be associated with a lower risk of incident cancer even when smoking was removed from the score. 30 In a large retrospective cohort, adherence to cancer guidelines for obesity, physical activity, and diet were associated with a reduction of cancer and ASCVD mortality. 31 Optimal management of cancer survivors involves increased awareness of worse oncological and cardiovascular outcomes in individuals with ASCVD and CRF, and early recognition and aggressive management of shared risk factors. As noted in our study ( Figure) , presence of ASCVD and poor risk profile in absence of ASCVD was not only associated with much higher subspecific absolute costs, but also a significant proportion of costs (30%) were related to hospitalizations. On the other hand, among cancer patients in absence of a diagnosis of ASCVD, among patients with average and optimal CRF, hospitalizations contributed to nearly 15% of overall expenditures, with a major proportion (%40%) of all costs related to outpatient visits. These findings support the focus of current healthcare reforms for value-based health care, emphasizing an integrated population health on lowering overall healthcare costs by shifting care from hospital-based services to ambulatory. Our results provide cost estimates for potential cost savings by incorporating preventive strategies of modifiable CRF for cancer survivors to mitigate progression to ASCVD and reduce the associated comorbid cost burden. 32 
Study Limitations
Continued
were defined as any individual who has ever been diagnosed with cancer regardless of duration as previously described. 6 Second, the MEPS data only capture a fraction of total national health expenditures for cancer patients. For example, nursing home expenditures attributable to cancer are excluded. 33 Cancer patients with advanced disease were likely not able to participate in the survey, further underestimating cancer costs. The true burden of cancer goes beyond medical costs and includes lost productivity, stress, mental health, costs for travel and child care, and costs incurred by caretakers. 34 Other analyses have reported an underestimation of total medical expenditures from MEPS data, which all suggest our results are a conservative estimate for the burden of modifiable CRF on cancer patients as well as the estimated savings from prevention strategies, 33, 35, 36 therefore strengthening our findings. Third, because cancer, ASCVD, and modifiable CRF were self-reported, there is likely an underrepresentation of the true national prevalence, as has previously been described. 37, 38 The prevalence of ASCVD in this study was lower than previous national estimates (15.7% versus 36%), in part because we excluded hypertension, as it was included in the CRF profile. 2 Fourth, lack of information on dietary habits did not allow us to include this important modifiable risk factor. Additionally, because of the lack of clinical factors (blood pressure, fasting blood glucose, and total cholesterol), we were not able to calculate American Heart Association's ideal health cardiovascular status (Life's Simple 7). Fifth, there is a risk of residual confounding from unmeasured characteristics that could affect our study outcomes, despite our best attempts to comprehensively control for the most importantly observed contributing variables. Lastly, the results only apply to the noninstitutionalized adult US population.
Conclusions
From a contemporary nationally representative population, we found that the absence of ASCVD and a favorable cardiovascular risk factor profile among cancer survivors was associated with significantly lower healthcare expenditure and resource utilization. These results provide robust estimates for potential healthcare savings as preemptive strategies continue to become integrated into new healthcare delivery models, for increased awareness and prevention of ASCVD, 
